-
Media ReleaseNovartis recognized as top ranking company in the US on DiversityInc Top 50 Companies for Diversity list
-
Media ReleaseNovartis reports new Phase III data showing secukinumab (AIN457) improved moderate-to-severe plaque psoriasis in patients
-
Media ReleaseNovartis personalized cell therapy CTL019 receives FDA Breakthrough Therapy designation
-
Media ReleasePivotal data for Novartis' investigational compound LDE225 show marked tumor responses in advanced basal cell carcinoma
-
Media ReleaseNovartis presents key advances in cancer research at ASCO and EHA from four new pivotal studies in lung, blood and skin cancers
-
Media ReleaseNovartis' new heart failure medicine LCZ696 cut cardiovascular deaths by 20% vs. ACE-inhibitor in landmark PARADIGM-HF trial
-
Media ReleaseNovartis to showcase heart failure leadership at ESC Congress 2014 with results on new first of its type medicine LCZ696
-
Media ReleaseNovartis announces NEJM publication of two pivotal Phase III secukinumab studies demonstrating statistically significant skin clearance in psoriasis patients
-
Media ReleaseNovartis announces FDA Advisory Committee unanimously recommends approval of AIN457 (secukinumab) for patients with moderate-to-severe plaque psoriasis
-
Media ReleaseNovartis announces CTL019 data published in NEJM demonstrating efficacy in certain patients with acute lymphoblastic leukemia (ALL)
-
Media ReleaseNovartis drug Afinitor® is first treatment for advanced pancreatic NET to provide overall survival of more than 3.5 years in Phase III trial
-
Media ReleaseNovartis AIN457 (secukinumab) showed significant symptom improvement in two pivotal Phase III ankylosing spondylitis studies